Cargando…

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis

BACKGROUND: Pegylated interferon and ribavirin (PEG-IFN+RBV) may be more cost-effective than direct-acting antivirals in resource-limited settings. Current literature suggests sustained virological response (SVR) in hepatitis C virus genotype 4 (HCV-4) is similar to genotype 1 (HCV-1), but worse tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yee, Brittany E, Nguyen, Nghia H, Zhang, Bing, Lin, Derek, Vutien, Philip, Wong, Carrie R, Lutchman, Glen A, Nguyen, Mindie H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599167/ https://www.ncbi.nlm.nih.gov/pubmed/26462288 http://dx.doi.org/10.1136/bmjgast-2015-000049

Ejemplares similares

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
por: Nguyen, Nghia H, et al.
Publicado: (2016)

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience
por: Nguyen, Peter, et al.
Publicado: (2017)

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care
por: Vu, Vinh D, et al.
Publicado: (2015)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
por: Gilman, Andrew J, et al.
Publicado: (2018)

Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States
por: Vutien, Philip, et al.
Publicado: (2016)

Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection
por: Rao, Huiying, et al.
Publicado: (2014)

Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study
por: Ladenheim, Maya R, et al.
Publicado: (2016)

Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia
por: Kim, Yoona A, et al.
Publicado: (2016)

Quasispecies characteristic in “a” determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case–control study
por: Xiao, Yiwei, et al.
Publicado: (2020)

Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects
por: Abdo, Ayman A., et al.
Publicado: (2009)

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2016)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
por: Han, Sung Yong, et al.
Publicado: (2021)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription
por: Salerno, Debora, et al.
Publicado: (2020)

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
por: Zhang, H W, et al.
Publicado: (2008)

Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients
por: Huang, Chung-Feng, et al.
Publicado: (2013)

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2019)

Low yield of head CT in cirrhotic patients presenting with hepatic encephalopathy
por: Hanna, Angy, et al.
Publicado: (2021)

Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection
por: Feng, Bo, et al.
Publicado: (2014)

Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis
por: Saeki, Chisato, et al.
Publicado: (2022)

Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population
por: Huong, Nguyen Thi Cam, et al.
Publicado: (2022)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
por: Zaimi, Yosra, et al.
Publicado: (2021)

An educational tool for the prophylaxis of hepatic encephalopathy
por: Garrido, Maria, et al.
Publicado: (2017)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C
por: Isfordink, Cas J, et al.
Publicado: (2020)

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice
por: Zhang, Tian-Ying, et al.
Publicado: (2020)

Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
por: Mengshol, J A, et al.
Publicado: (2009)

Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
por: Enomoto, Masaru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5rh9t0rp5hvvpsgglsvbe220ce